Top Markets
Coin of the day
Evaxion Biotech A/S Evaxion Biotech A/S

Evaxion Biotech A/S

EVAX
Rank in Stocks #29741
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to... Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Share Price
$3.14
Last synced: 2026-08-18
Market Cap
$19.83M
Change (1 day)
0.32%
Change (1 year)
3.29%
Country
DK
Trade Evaxion Biotech A/S (EVAX)

Category

Earnings for Evaxion Biotech A/S (EVAX)
Earnings in 2026 TTM: 0
According to Evaxion Biotech A/S latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Evaxion Biotech A/S from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH
- -
KR